SNMMI's communications staff is available to handle your inquiries, arrange interviews with experts, provide copies of research articles and more.
For assistance, please contact Rebecca Maxey, director of communications, at email@example.com or (703) 652-6772.
SNMMI is dedicated to being the premier source of information on nuclear medicine and molecular imaging. The society's online newsroom provides reporters with the information needed to write articles and gain background information on the many topics related to nuclear medicine, molecular imaging and therapy.
SNMMI issues press releases on new research, society updates and industry news for members of the press. Check back frequently to see what's new with SNMMI.
View press releases on the latest research and news from SNMMI.
Please see Tab 6 for information about SNMMI's 2024 Annual Meeting.
Nuclear and molecular imaging are vital elements of today's medical practice, adding an additional dimension to diagnosis that can change the way diseases are understood and treated. Nuclear medicine therapies treat specific diseases, such as lymphoma or thyroid cancer, by allowing a high dose of medicine to be delivered directly to a tumor or problem area. SNMMI's fact sheets explain how nuclear medicine and molecular imaging can help diagnose and/or treat a wide range of diseases.
SNMMI publishes two peer-reviewed medical journals—The Journal of Nuclear Medicine (JNM) and The Journal of Nuclear Medicine Technology (JNMT)—which feature the latest in molecular imaging research. JNM and JNMT are the most widely read peer-reviewed publications in molecular imaging, nuclear medicine and allied disciplines.
Every month, JNM brings readers around the globe key research articles on theranostics, nuclear medicine therapy, and imaging of cancer, neurological disease, cardiological disease, and other disease as well as continuing education articles and updates on rapidly changing issues in practice and research.
Published quarterly, JNMT focuses on technology, quality assurance, radiation safety, and the clinical applications of nuclear medicine. Each issue features continuing education articles written by leading educators in nuclear medicine technology as well as news and updates on practice, licensure, and credentialing for nuclear medicine technologists. Practitioners from across the imaging sciences turn to JNMT for peer-reviewed information related to daily clinical practice.
SNMMI can connect you with subject-matter experts on a variety of topics who are ready to respond to tight deadlines. Contact Rebecca Maxey, director of communications, at firstname.lastname@example.org or at (703) 652-6772, to set up an interview with SNMMI's leadership or with one of its many experts on oncology, brain disease, heart disease, radiopharmaceuticals, reimbursement and more.
Join SNMMI on our social media networks to stay updated on the latest from the society and the nuclear medicine and molecular imaging field.
The SNMMI Annual Meeting is recognized as the premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging. The four-day event, which generally takes place each June, provides physicians, technologists, pharmacists, laboratory professionals, and scientists with an in-depth view of the latest research and development in the field and the clinic.
The SNMMI 2024 Annual Meeting will take place June 8–11, 2024, at Metro Toronto Convention Centre in Toronto, ON, Canada.
Leading molecular imaging and nuclear medicine physicians, radiologists, cardiologists, pharmacists, scientists, lab professionals, and technologists, representing the world's top medical and academic institutions and centers. The 2023 Annual Meeting attracted nearly 8,000 registrants.
The 2024 Annual Meeting will feature an exceptional program highlighted by some of the hottest topics in nuclear medicine and molecular imaging, including the latest scientific research, an extensive exhibit hall, networking events, and more.
Research to be presented in oral scientific sessions is embargoed until the presentation has ended. There is no embargo on posters.
SNMMI offers free registration to accredited members of the press or writers who can supply a letter of assignment from a publication or media outlet. Registration provides access to all open educational sessions, the exhibit area, and press room.
Pre-registration is required. Members of the media should register by contacting Rebecca Maxey at email@example.com or (703) 652-6772.
The SNMMI Press Office is TBD. An SNMMI press liaison will be present to handle media requests.
Saturday, June 8 — 1:00−5:00 pm
Sunday, June 9 — 10:00 am−5:30 pm
Monday, June 10 — 10:00 am−5:30 pm
Tuesday, June 11 — 8:00 am−TBA
Follow us on Twitter @SNM_MI for the latest updates from the meeting; our official hashtag is #SNMMI24.
Event details and program information will be available in early 2024 on the SNMMI website.
Nuclear medicine has the potential to change the landscape of theranostics in neurooncology, according to a new article in JNM. With recent advances in techniques to permeate the brain-blood barrier, the prospect of using radiopharmaceuticals to treat brain tumors is promising.
PRRT is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in JNM. In the largest study to date of metastatic insulinoma patients treated with PRRT, more than 80 percent of patients had long-lasting symptom control, and nearly 60 percent were able to reduce the use of other drugs to treat the disease.
A novel PET imaging technique can noninvasively detect active inflammation in the body —such as rheumatoid arthritis—before clinical symptoms arise, according to research published in JNM.
More than 700 attendees from around the world gathered in Orlando, Florida, on February 1-3 for the SNMMI Mid-Winter and ACNM Annual Meeting.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.